title: [Berberine regulates glycemiavialocal inhibition of intestinal dipeptidyl peptidase-Ⅳ].
abstract: Objective:To investigate the effect of berberine on glycemia regulation in rats with diabetes and the related mechanisms.Methods:Diabetic-like rat model was successfully induced by intraperitoneal injection of streptozotocin in 50 out of 60 male SD rats, which were then randomly divided into 5 groups with 10 rats in each:control group (received vehicle only), positive drug control group (sitagliptin 10 mg·kg-1·d-1), low-dose berberine group (30 mg·kg-1·d-1), moderate-dose berberine group (60 mg·kg-1·d-1), and high-dose berberine group (120 mg·kg-1·d-1). All animals were fed for 3 d, and fasting blood sampling was performed on day 3 of administration. Rats were given glucose (2 g/kg) by gavage 30 min after the last dose. Blood and intestinal samples were obtained 2 h after glucose loading. Fasting blood glucose (FBG) and 2-h postprandial plasma glucose (2h-PPG) were detected by using biochemical analyzer, and insulin, glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-Ⅳ(DPP-Ⅳ) were measured by using ELISA kit.Results:No significant difference in FBG and serum DPP-Ⅳ level were found between berberine groups and control group (allP>0.05). Compared with control group, serum levels of GLP-1 and insulin were increased in high-and moderate-dose berberine groups, while 2h-PPG was decreased (allP<0.05); GLP-1 levels in the intestinal samples were increased, while DPP-Ⅳ levels were decreased in all berberine groups (allP<0.05).Conclusions:Short-term berberine administration can decrease 2h-PPG level in streptozotocin-induced diabetic rat model through local inhibition of intestinal DPP-Ⅳ. The efficacy of DPP-Ⅳ inhibitor may be associated with its intestinal pharmacokinetics.
authors.affiliation: Department of Cadre Health, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China.
authors.forename: Jiesheng
authors.initials: J
authors.lastname: Wang
authors.affiliation: Basic Laboratory, Institute of Traditional Chinese Medicine of Zhejiang Province, Hangzhou 310007, China.
authors.forename: Guanhai
authors.initials: G
authors.lastname: Dai
authors.affiliation: Department of Endocrinology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China. liweijia0209@163.com.
authors.forename: Weijia
authors.initials: W
authors.lastname: Li
mesh_terms: D000818:Animals; D001599:Berberine / Q000493:pharmacokinetics / Q000494:pharmacology*; D001786:Blood Glucose / Q000187:drug effects*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4 / Q000032:analysis* / Q000187:drug effects* / Q000493:pharmacokinetics; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004305:Dose-Response Relationship, Drug; D052216:Glucagon-Like Peptide 1 / Q000032:analysis / Q000097:blood; D007004:Hypoglycemic Agents; D007328:Insulin / Q000097:blood; D007422:Intestines / Q000737:chemistry / Q000187:drug effects; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068900:Sitagliptin Phosphate
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D001599:Berberine; D052216:Glucagon-Like Peptide 1; C000602659:DPP4 protein, rat; D018819:Dipeptidyl Peptidase 4; D000068900:Sitagliptin Phosphate